Short Interest in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Expands By 34.8%

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was the target of a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 33,200,460 shares, a growth of 34.8% from the January 29th total of 24,620,718 shares. Approximately 10.3% of the company’s stock are short sold. Based on an average daily volume of 8,624,264 shares, the short-interest ratio is currently 3.8 days. Based on an average daily volume of 8,624,264 shares, the short-interest ratio is currently 3.8 days. Approximately 10.3% of the company’s stock are short sold.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SGMO. World Investment Advisors lifted its holdings in shares of Sangamo Therapeutics by 88.5% in the 3rd quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 20,000 shares during the period. Cetera Investment Advisers purchased a new position in Sangamo Therapeutics during the fourth quarter valued at approximately $31,000. XTX Topco Ltd acquired a new position in Sangamo Therapeutics in the second quarter valued at approximately $41,000. Engineers Gate Manager LP boosted its position in Sangamo Therapeutics by 101.7% in the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 44,078 shares in the last quarter. Finally, State of Wyoming acquired a new stake in shares of Sangamo Therapeutics during the 4th quarter worth approximately $47,000. Institutional investors and hedge funds own 56.92% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on SGMO shares. Barclays reissued an “equal weight” rating and set a $1.00 price objective (down from $5.00) on shares of Sangamo Therapeutics in a report on Friday, November 7th. Wall Street Zen downgraded Sangamo Therapeutics to a “strong sell” rating in a report on Saturday, January 31st. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, February 10th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sangamo Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.33.

Sangamo Therapeutics Price Performance

Sangamo Therapeutics stock traded up $0.01 during midday trading on Wednesday, reaching $0.40. The company’s stock had a trading volume of 633,341 shares, compared to its average volume of 6,395,965. The stock has a market capitalization of $135.30 million, a P/E ratio of -0.91 and a beta of 1.33. The stock’s 50-day simple moving average is $0.42 and its 200-day simple moving average is $0.50. Sangamo Therapeutics has a 52-week low of $0.35 and a 52-week high of $1.06.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.